• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 31, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Combinations of paclitaxel and withaferin A against human non-small cell lung cancer

Bioengineer by Bioengineer
April 22, 2020
in Health
Reading Time: 4 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Oncotarget Volume 11 Issue 16 showed that the sensitivity of H1299 and A549 cells to concomitant treatment with PAC and WFA was greater than that of either PAC or WFA alone

IMAGE

Credit: Correspondence to – Ramesh C. Gupta – [email protected] and Farrukh Aqil – [email protected]

Oncotarget Volume 11 Issue 16 showed that the sensitivity of H1299 and A549 cells to concomitant treatment with PAC and WFA was greater than that of either PAC or WFA alone.

Interestingly, the synergism of PAC and WFA was not schedule-dependent but was enhanced when cells were pretreated with WFA indicating a chemo-sensitizing effect.

Taken together, the results demonstrate the efficacy of WFA alone or alongside PAC on NSCLC cells and provide a strong rationale for further detailed testing in clinically relevant models for the development of PAC+WFA combination as an alternative therapeutic strategy for advanced NSCLC.

Dr. Ramesh C. Gupta from The Department of Pharmacology and Toxicology and The James Graham Brown Cancer Center at The University of Louisville as well as Dr. Farrukh Aqil from The Department of Medicine and The James Graham Brown Cancer Center at The University of Louisville said, “Lung cancer remains the leading cause of cancer-related deaths among both men and women in the U. S and worldwide.”

The therapeutic options for NSCLC following diagnosis are dependent upon the clinical stage at diagnosis with surgical resection being the standard of care for early-stage NSCLC.

This is true primarily because 50% of tumor cells.

Therefore, despite these recent therapeutic advancements, NSCLC remains largely incurable, and the overall clinical benefit of current therapies in NSCLC is still marginal and temporary.

While PAC and cis-Pt display high antitumor potency and efficacy against all subtypes NSCLC, this chemotherapy suffers from a lack of selectivity, dose-limiting toxicity, drug resistance, and metastasis which have plateaued the clinical efficacy at about 10-14 months.

Currently, the findings demonstrate that various combinations of PAC and WFA are highly synergistic against the proliferation of the human NSCLC cells, H1299, and A549.

Moreover, WFA was active against PAC-sensitive and PAC-resistant NSCLC cells thus demonstrating the potential therapeutic efficacy of WFA alone, and in combination with PAC against NSCLC cells and providing a strong rationale for further testing to advance this combination in clinical trials.

The Gupta/Aqil Research Team concluded in their Oncotarget Research Paper that Since cis-Pt alongside PAC is the current first-line chemotherapy for NSCLC without driver genetic mutations, they have shown that PAC with WFA is more potent and more efficacious than the standard of care.

More importantly, WFA was active against both drug-sensitive and drug-resistant cells which further broadens the scope and relevance of the PAC+WFA combination in NSCLC.

###

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27519

Full text – https://www.oncotarget.com/article/27519/text/

Correspondence to – Ramesh C. Gupta – [email protected] and Farrukh Aqil – [email protected]

Keywords – non-small cell lung cancer, withaferin A, synergistic, combination index, paclitaxel

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget

Facebook – https://www.facebook.com/Oncotarget/

Twitter – https://twitter.com/oncotarget

LinkedIn – https://www.linkedin.com/company/oncotarget

Pinterest – https://www.pinterest.com/oncotarget/

Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

[email protected]

18009220957×105

Media Contact
Ryan James Jessup
[email protected]

Original Source

https://www.oncotarget.com/news/pr/combinations-of-paclitaxel-and-withaferin-a-against-human-non-small-cell-lung-cancer/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27519

Tags: cancerCarcinogensMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Time Pressure Impact on Finnish Home Care Nurses

October 31, 2025

Diabetes Fatalism: Impact on Outcomes in African Americans

October 31, 2025

Assessing Ergonomics in Special Needs Kindergarten Settings

October 31, 2025

Prenatal Probiotics: Boosting Neonatal Gut Development

October 31, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1292 shares
    Share 516 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    202 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    136 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Time Pressure Impact on Finnish Home Care Nurses

Empowering Cancer Care in Bangladesh Through Collaboration

Efficient H2O2 Production Boosted by Cobalt-Enhanced Phosphate-Functionalized Reduced Graphene Oxide/Perylenetetracarboxylic Acid Nanosheet Heterojunctions

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.